Skip to main content
SpringerLink
Log in

Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment

  • Chapter
Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis

Part of the book series: Topics in Neuroscience ((TOPNEURO))

  • 151 Accesses

Abstract

It is hard to account for all the features of multiple sclerosis by episodes of demyelination and remyelination alone: the rapidity of recovery from a relapse, for instance, or the transition from relapsing-remitting disease to progressive accumulation of disability. Here, we report observation from the close study of a small number of patients treated with an experimental agent, Campath-1H, that cast some light on these issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benjamin RJ, Waldmann H (1986) Induction of tolerance by monoclonal antibody therapy. Nature 320:449–451

    Article  PubMed  CAS  Google Scholar 

  2. Qin S, Cobbold SP, Pope H, Helliott J, Kioussis D, Davies J et al (1993) ‘Infectious’ transplantation tolerance. Science 259:974–977

    Article  PubMed  CAS  Google Scholar 

  3. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H et al (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum apears in Lancet (1994) 486]. Lancet 344:298–301

    Article  PubMed  CAS  Google Scholar 

  4. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H et al (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119:225–237

    Article  PubMed  Google Scholar 

  5. Charpentier B, Hiesse C, Lantz O, Ferran C, Stephens S, O’Shaugnessy D et al (1992) Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 54:997–1002

    Article  PubMed  CAS  Google Scholar 

  6. Coles AJ, Wing M, Molyneux P, Paolillo A, Davies C, Hale G, Miller d, Waldmann H, Compston A (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304

    Article  PubMed  CAS  Google Scholar 

  7. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    Article  PubMed  CAS  Google Scholar 

  8. Branch DR, Shah A, Guilbert LJ (1991) A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J Immunol Methods 143:251–261

    Article  PubMed  CAS  Google Scholar 

  9. Hay H, Cohen J (1989) Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J Clin Lab Immunol 29:151–155

    PubMed  CAS  Google Scholar 

  10. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne Cain ML, McDonald WI et al (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009–2019

    Article  PubMed  Google Scholar 

  11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231

    Article  PubMed  CAS  Google Scholar 

  12. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG et al (1991) The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 114:2437–2450

    Article  PubMed  Google Scholar 

  13. Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction:demyelinated axons are especially susceptible. Brain 120:2149–2157

    Article  PubMed  Google Scholar 

  14. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H et al (1997) Characterization of MRI response to treatment with interferon beta-lb: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49:862–869

    Article  PubMed  CAS  Google Scholar 

  15. Rudge P, Miller D, Crimlisk H, Thorpe J (1995) Does interferon beta cause initial exacerbation of multiple sclerosis? (letter) Lancet 345:580

    Article  PubMed  CAS  Google Scholar 

  16. Stone LA, Albert PS, Smith ME, De Carli C, Armstrong MR, McFarlin DE et al (1995) Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 45:1808–1814

    Article  PubMed  CAS  Google Scholar 

  17. Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L et al (1998) Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43:332–339

    Article  PubMed  CAS  Google Scholar 

  18. Hawkins CP, Mackenzie F, Tofts P, du Boulay EP, McDonald WI (1991) Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 114:801–810

    Article  PubMed  Google Scholar 

  19. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34:661–669

    Article  PubMed  CAS  Google Scholar 

  20. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793

    Article  PubMed  CAS  Google Scholar 

  21. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-lb treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-lb in secondary progressive multiple sclerosis. Brain 123:2256–2263

    Article  PubMed  Google Scholar 

  22. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698–1704

    Article  PubMed  CAS  Google Scholar 

  23. Ferguson B, Matyszak MK, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399

    Article  PubMed  Google Scholar 

  24. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285

    Article  PubMed  CAS  Google Scholar 

  25. Coles A, Wing M, Smith S, Corradu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment modulates T cell responses in multiple sclerosis but induces autoimmune thyroid disease. Lancet 354:1691–1695

    Article  PubMed  CAS  Google Scholar 

  26. Colello RJ, Pott U, Schwab ME (1994) The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J Neurosci 14:2594–2605

    PubMed  CAS  Google Scholar 

  27. Kaplan MR, Meyer Franke A, Lambert S, Bennett V, Duncan ID, Levinson SR et al (1997) Induction of sodium channel clustering by oligodendrocytes. Nature 386:724–728

    Article  PubMed  CAS  Google Scholar 

  28. Meyer Franke A, Kaplan MR, Pfrieger FW, Barres BA (1995) Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 15:805–819

    Article  PubMed  CAS  Google Scholar 

  29. Pfrieger FW, Barres BA (1997) Synaptic efficacy enhanced by glial cells in vitro. Science 277:1684–1687

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. J. Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. G. Wing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Molyneux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Paolillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. M. Davie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Waldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Compston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. European Charcot Foundation, Nijmegen, The Netherlands

    Otto R. Hommes

  2. Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

    Giancarlo Comi

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Italia

About this chapter

Cite this chapter

Coles, A.J. et al. (2004). Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment. In: Hommes, O.R., Comi, G. (eds) Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-2117-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2117-4_2

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2171-6

  • Online ISBN: 978-88-470-2117-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation